Yuliya. V. Zhernakova

Yuliya. V. Zhernakova

Auto-generated profile, based on publicly available information

Yuliya. V. Zhernakova

E.I. Chazov National Medical Research Center Of Cardiology

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
SBSergey Boytsov
Sergey Boytsov
ODOxana M. Drapkina
Oxana M. Drapkina
ESE. V. Shlyakhto
E. V. Shlyakhto
AKA. O. Konradi
A. O. Konradi
YBYulia Balanova
Yulia Balanova
SSSvetlana Shalnova
Svetlana Shalnova
The growing weight of noncommunicable diseases, primarily cardiovascular diseases (CVDs), is a great threat to the health of population worldwide, worsening the quality of life and reducing life expectancy. Realization of this threat led to initiation of epidemiological study by the Russian Ministry of Health to investigate the prevalence of CVDs and their risk factors, since it is CVDs that specify the high allcause mortality in Russia. In the modern history of epidemiology of non-infectious disease, the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study occupies a special place. This is the largest epidemiological study, which is considered as a continuation of preventive activity in order to obtain unbiased information on epidemiological characteristics of population in Russian regions. To conduct the study, the Research Organizing Committee of ESSE-RF study was created and a protocol was developed. All interested scientists and experts from following three centers took part in the work: National Medical Research Center for Therapy and Preventive Medicine, Almazov National Medical Research Center, National Medical Research Center of Cardiology. The Russian regions were justified and selected for participation. In 2012-2014 ESSE-RF study, 13 following Russian regions took part: Volgograd, Vologda, Voronezh, Ivanovo, Kemerovo, Tyumen Oblasts; Krasnoyarsk and Primorsky Krai; the Republic of North Ossetia (Alania); cities of Orenburg, Samara, St. Petersburg and Tomsk. All participated regions used a single study protocol, while biochemical parameters were determined in Federal centers using the same equipment and reagent kits. The paper presents some of the most interesting results that indicate a change in Russian epidemiological situation over the past few years. After the end of cross-sectional study, a field of priority research areas was formed in each center.Conclusion. Epidemiological studies are the most important scientific tool for assessing the prevalence of diseases, their risk factors, as well as predicting adverse events. Based on the results obtained, healthcare system and medical community determine priorities and develop related strategies (population-based and high-risk strategies). For their implementation, a regulatory and legal framework is being created.

15 October 2018 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
YZYu V Zhernakova
Yu V Zhernakova
EZE A Zheleznova
E A Zheleznova
ICI E Chazova
I E Chazova
EOE V Oshchepkova
E V Oshchepkova
YDYu A Dolgusheva
Yu A Dolgusheva
ЯБЯровая Елена Борисовна
Яровая Елена Борисовна
Abdominal obesity (AO) is a predictor of cardiovascular disease and diabetes mellitus type 2. The assessment of the disease prevalence and the study of socioeconomic status of people with this phenotype of obesity are necessary to develop effective mechanisms to combat this risk factor in the population. The aim of the study is to determine the prevalence of AO in the population and to assess the association with socioeconomic factors according to the data of the ESSE-RF study (Epidemiology of Cardiovascular diseases in the Regions of the Russian Federation). Materials and methods. The object of the study is a random population sample of men and women aged 25-64 years from 13 regions of the Russian Federation (n=21 817). Abdominal obesity in men was defined as waist circumference (WC) >94 cm, and in women - WC >80 cm. Body mass index (BMI) >30.0 kg/m2 was adopted as the criterion of common obesity. Results and discussion. The prevalence of AO in Russia was 55% (61.8% in women and 44% in men), while the percent of people with obesity, defined by BMI was significantly lower (33.4%). The number of examined patients with AO increased with age among both men and women (p

15 December 2019 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICIrina E Chazova
Irina E Chazova
JZJuliya V Zhernakova
Juliya V Zhernakova
OKOksana A Kisliak
Oksana A Kisliak
SNSergey V Nedogoda
Sergey V Nedogoda
VPValery I Podzolkov
Valery I Podzolkov
ОВОщепкова Елена Владимировна
Ощепкова Елена Владимировна
Substantial amount of epidemiologic studies showed that hyperuricemia is highly associated with cardiovascular disorders, chronic renal disease, and diabetes mellitus development risk. This fact shows necessity of increased focus on uric acid level in serum not only in relation to rheumatic disorders but also in relation to cardiovascular and renal risk. European Society of Cardiology and Russian Arterial Hypertension Society experts included tests on uric acid level serum concentration in routine tests for hypertensive patients. Important steps in increase of hyperuricemia control in clinical practice are increase of awareness as a risk factor of cardiovascular disorders, development of risk management algorithm for patients with hyperuricemia and high cardiovascular risk, and increase of treatment adherence. Decrease of uric acid level in serum achieved after treatment with urate decreasing therapy mostly with xanthine oxidase inhibitor is associated with improvement of blood pressure control and decrease of cardiovascular adverse events frequency.

25 December 2024 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
NCN. M. Chikhladze
N. M. Chikhladze
NBN. V. Blinova
N. V. Blinova
AAA. V. Aksenova
A. V. Aksenova
TAT. A. Alekseeva
T. A. Alekseeva
GSG. V. Shchelkova
G. V. Shchelkova
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.

24 November 2015 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
SSSvetlana Shalnova
Svetlana Shalnova
ROR. G. Oganov
R. G. Oganov
ADA. D. Deev
A. D. Deev
AIAsiia (Asiya) Imaeva
Asiia (Asiya) Imaeva
МLМ. М. Lukyanov
М. М. Lukyanov
ЯДЯ. В. Данильченко
Я. В. Данильченко
Цель. Изучить распространенность ишемической болезни сердца, как одного из частых сердечно-сосудистых заболеваний, в сочета­нии с артериальной гипертонией (АГ), сахарным диабетом (СД) и заболеваниями печени (ЗП) в популяции взрослого населения (25-64 лет) ряда регионов РФ, их распределение по полу и возрасту и ассоциации с сердечно-сосудистыми факторами риска (ФР). Материал и методы. В анализ включены результаты изучения представительных выборок 13 регионов РФ, обследованных по программе многоцентрового исследования ЭССЕ-РФ в 2012­2013гг; всего были обследованы 21923 человека. Обследование включало опрос по стандартной анкете, содержащей информацию о заболеваниях в анамнезе. При статистической обработке исполь­зован пакет прикладных программ SAS. Результаты. У мужчин распространенность ИБС ассоциируется с ростом коморбидности от 0 в возрастной группе 25-34 лет до 77% в возрасте 55-64 лет, практически удваиваясь в каждом десятилетии. У женщин отмечается аналогичная тенденция, но менее выраженная. У мужчин имеют место значимые ассоциа­ции только с АГ, которая в 2,5 раза увеличивает риск развития ИБС, тогда как у женщин наряду с АГ значимыми являются ассоци­ации с ЗП. Сочетания с СД не влияют на частоту ИБС у мужчин и женщин. В то же время любое сочетание с двумя заболеваниями увеличивает риск наличия ИБС в >3-4 раза. Наиболее неблагопри­ятно сочетание всех трех болезней, при которых ИБС выявляется в 8,7 раза чаще, чем при их отсутствии. При использовании много­мерной логистической регрессии после коррекции на возраст и коморбидность у больных ИБС обоего пола были выявлены ассо­циации с уровнем холестерина липопротеинов высокой плотности (ХС-ЛВП) в крови и абдоминальным ожирением. У мужчин допол­нительно отмечены положительные ассоциации с курением и отрицательные — с повышенным ХС. Заключение. Сочетания ИБС с АГ, СД и ЗП в популяции взрослого населения встречаются часто, ассоциируются с общими ФР, увели­чиваются с возрастом. Учитывая современные тенденции быстрого старения населения, следует ожидать увеличения распространен­ности коморбидных состояний, что диктует необходимость адапта­ции служб здравоохранения к этим изменениям.

28 October 2020 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICIrina E. Chazova
Irina E. Chazova
VNVera A. Nevzorova
Vera A. Nevzorova
LALali G. Ambatiello
Lali G. Ambatiello
TBTat’iAna A. Brodskaia
Tat’iAna A. Brodskaia
EOElena V. Oshchepkova
Elena V. Oshchepkova
БСБелевский Андрей Станиславович
Белевский Андрей Станиславович
One of the most common comorbid condition in people over 40 years old is: arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD). The frequency of AH in patients with COPD varies from 6.8 to 76.3%, in average 34.3%. COPD is detected in every fourth patient with hypertension in the age group of 2564 years. The current trend towards an increase in life expectancy and therefore growing pool of elder cohort, will lead to a higher number of patients with comorbid disorders. Diagnosis and treatment of AH and COPD are determined by current clinical recommendations for both nosologies, however, a number of mutual pathophysiological mechanisms lead to a more severe course of these diseases with frequent exacerbations. The choice of antihypertensive therapy in patients with AH in combination with COPD should be given to drugs that can provide an adequate decrease in blood pressure in hypoxic conditions, especially at night and early morning hours, that have prolonged effect or could be prescribed in the evening, and to those that dont worsen bronchial obstruction or exacerbate hypoxia. Patients with AH and COPD should be given recommendations on lifestyle changes, especially smoking cessation. As initial therapy calcium channel blockers, angiotensin receptor blockers or angiotensin-converting enzyme inhibitors should be considered. Calcium channel blockers/renin-angiotensin system blockers should be considered as the first line for combination therapy. Thiazide, thiazide-like diuretics orb1-selective adrenergic blockers could be prescribed in case of insufficient antihypertensive response or depending on different clinical scenarios. Bronchodilators are the baseline therapy in COPD with concomitant AH. According to modern concepts, prescription of combination therapy with different mechanisms of action is the most proven and justified approach, which leads to a decrease in the frequency of exacerbations of COPD and amelioration of the symptoms. The choice of bronchodilator in the case of a COPD and AH combination, should take into account the proven long-term safety regarding the risk of cardiovascular complications. Tiotropium bromide as the monotherapy, including as a liquid inhaler and aclidinium/formoterol, tiotropium/oladeterol as combination therapy showed cardiovascular safety in the long-term studies. The escalation of COPD therapy with the need of inhaled steroids requires careful monitoring of blood pressure and, possibly, a revision of antihypertensive treatment leading to its escalation as well. COPD has many phenotypes requiring different medications, eg.: roflumilast, theophylline, macrolides and mucoactive drugs, that could also require tighter blood pressure control on patients with COPD and AH.